BR112015029299A2 - subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares - Google Patents
subpopulação de monócitos humanos para tratamento de doenças e distúrbios ocularesInfo
- Publication number
- BR112015029299A2 BR112015029299A2 BR112015029299A BR112015029299A BR112015029299A2 BR 112015029299 A2 BR112015029299 A2 BR 112015029299A2 BR 112015029299 A BR112015029299 A BR 112015029299A BR 112015029299 A BR112015029299 A BR 112015029299A BR 112015029299 A2 BR112015029299 A2 BR 112015029299A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- cells
- monocyte subpopulation
- disorders
- eye diseases
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title abstract 4
- 210000001616 monocyte Anatomy 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000001328 optic nerve Anatomy 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826159P | 2013-05-22 | 2013-05-22 | |
| US201361915069P | 2013-12-12 | 2013-12-12 | |
| PCT/IL2014/050463 WO2014188436A1 (en) | 2013-05-22 | 2014-05-22 | Human monocyte sub-population for treatment of eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015029299A2 true BR112015029299A2 (pt) | 2017-07-25 |
Family
ID=51933057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015029299A BR112015029299A2 (pt) | 2013-05-22 | 2014-05-22 | subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10188679B2 (https=) |
| EP (1) | EP2999479B1 (https=) |
| JP (1) | JP6474082B2 (https=) |
| KR (1) | KR102257163B1 (https=) |
| CN (1) | CN105377273A (https=) |
| AU (1) | AU2014269935B2 (https=) |
| BR (1) | BR112015029299A2 (https=) |
| CA (1) | CA2913274C (https=) |
| IL (1) | IL242694B (https=) |
| MX (1) | MX2015016062A (https=) |
| WO (1) | WO2014188436A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2790712B1 (en) * | 2011-12-14 | 2016-08-31 | Yeda Research and Development Co. Ltd. | Human monocyte sub-population for treatment of central nervous system injury |
| KR20260003355A (ko) | 2015-09-08 | 2026-01-06 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제 |
| DE102017125335B4 (de) * | 2017-10-27 | 2019-10-17 | Epiontis Gmbh | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| KR102228401B1 (ko) * | 2018-07-05 | 2021-03-16 | 고려대학교 산학협력단 | 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델 |
| BR112022011339A2 (pt) * | 2019-12-11 | 2022-10-04 | Myeloid Therapeutics Inc | Composições de células terapêuticas e métodos para fabricação e usos das mesmas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US5800812A (en) | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| AU2002353465B2 (en) | 2001-11-21 | 2008-10-16 | Yeda Research And Development Co. Ltd. | Process for the manufacture of human mononuclear phagocytic leukocytes |
| CA2598029A1 (en) * | 2005-02-24 | 2006-10-05 | The Scripps Research Institute | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| CA2752679A1 (en) | 2009-02-20 | 2010-08-26 | The Scripps Research Institute | Isolated monocyte populations and related therapeutic applications |
| EP2790712B1 (en) | 2011-12-14 | 2016-08-31 | Yeda Research and Development Co. Ltd. | Human monocyte sub-population for treatment of central nervous system injury |
-
2014
- 2014-05-22 CN CN201480039692.9A patent/CN105377273A/zh active Pending
- 2014-05-22 BR BR112015029299A patent/BR112015029299A2/pt not_active Application Discontinuation
- 2014-05-22 WO PCT/IL2014/050463 patent/WO2014188436A1/en not_active Ceased
- 2014-05-22 CA CA2913274A patent/CA2913274C/en active Active
- 2014-05-22 MX MX2015016062A patent/MX2015016062A/es unknown
- 2014-05-22 JP JP2016514532A patent/JP6474082B2/ja not_active Expired - Fee Related
- 2014-05-22 US US14/898,732 patent/US10188679B2/en active Active
- 2014-05-22 AU AU2014269935A patent/AU2014269935B2/en not_active Ceased
- 2014-05-22 EP EP14801769.2A patent/EP2999479B1/en active Active
- 2014-05-22 KR KR1020157036168A patent/KR102257163B1/ko not_active Expired - Fee Related
-
2015
- 2015-11-19 IL IL242694A patent/IL242694B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10188679B2 (en) | 2019-01-29 |
| EP2999479A4 (en) | 2017-02-22 |
| WO2014188436A1 (en) | 2014-11-27 |
| CN105377273A (zh) | 2016-03-02 |
| CA2913274C (en) | 2021-10-12 |
| KR20160016874A (ko) | 2016-02-15 |
| JP6474082B2 (ja) | 2019-02-27 |
| EP2999479B1 (en) | 2021-01-06 |
| AU2014269935A1 (en) | 2016-01-21 |
| US20160166612A1 (en) | 2016-06-16 |
| MX2015016062A (es) | 2016-08-03 |
| AU2014269935B2 (en) | 2019-01-24 |
| EP2999479A1 (en) | 2016-03-30 |
| JP2016522830A (ja) | 2016-08-04 |
| CA2913274A1 (en) | 2014-11-27 |
| KR102257163B1 (ko) | 2021-05-27 |
| IL242694B (en) | 2021-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502254A1 (en) | Methods and systems for modulating stimuli to the brain with biosensors | |
| CY1123735T1 (el) | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης | |
| BR112015029299A2 (pt) | subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares | |
| EA201891224A1 (ru) | Способы и системы для предоставления стимулов для головного мозга | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| UY33481A (es) | Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular | |
| BR112017014332A2 (pt) | métodos de tratamento de doenças retinianas | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| MY192843A (en) | Antibodies specific for tgf-beta | |
| BR112018074454A2 (pt) | composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal | |
| ES2571991T3 (es) | Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| MX2015002289A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso. | |
| BRPI0507807A (pt) | gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular | |
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| BR112013018919A2 (pt) | composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos | |
| CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
| MX2019006040A (es) | Composicion para promover la diferenciacion y proteccion de celulas madre neurales y metodo para inducir la regeneracion neural usando las mismas. | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |